On July 21, Insilico Medicine fell 5.43% in regular trading, trading at HKD 42.48/share, with turnover of HKD 181 million.

On the news front, the Life Sciences Tools & Services sector broadly weakened, with peers XtalPi down 3.33%, WuXi XDC down 1.33%, and WuXi AppTec down 0.64%. Additionally, two non-executive directors with Qiming Ventures and former Temasek backgrounds simultaneously resigned on July 15, following the expiration of the cornerstone investor lock-up period on June 29. Market concerns over potential stake disposals by early financial investors continue to weigh on sentiment, exerting short-term pressure on the share price.

It is worth noting that the company recently announced a positive profit alert for the first half, projecting revenue of approximately USD 103-107 million (up 272.7%-287.3% year-over-year) and a net profit of USD 33.5-39.5 million, marking a turnaround from losses. The company also secured multiple strategic partnerships during early July, including a deal with Takeda valued at up to USD 600 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)